[go: up one dir, main page]

BRPI0607844B8 - uso do egf e ghrp-6 - Google Patents

uso do egf e ghrp-6

Info

Publication number
BRPI0607844B8
BRPI0607844B8 BRPI0607844A BRPI0607844A BRPI0607844B8 BR PI0607844 B8 BRPI0607844 B8 BR PI0607844B8 BR PI0607844 A BRPI0607844 A BR PI0607844A BR PI0607844 A BRPI0607844 A BR PI0607844A BR PI0607844 B8 BRPI0607844 B8 BR PI0607844B8
Authority
BR
Brazil
Prior art keywords
nervous system
central nervous
ghrp
egf
neuroregeneration
Prior art date
Application number
BRPI0607844A
Other languages
English (en)
Inventor
Cibrian Vera Danay
Garcia Del Barco Herrera Diana
Penton Arias Eduardo
De Los Milagros Freyre Almeida Freya
Enrique Guillén Nieto Gerardo
Amador Berlanga Acosta Jorge
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of BRPI0607844A2 publication Critical patent/BRPI0607844A2/pt
Publication of BRPI0607844B1 publication Critical patent/BRPI0607844B1/pt
Publication of BRPI0607844B8 publication Critical patent/BRPI0607844B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uso do egf e ghrp-6. a presente invenção é dirigida a estimular a neuroregeneração do sistema nervoso central em função do dano autoimune. mm particular a combinação farmacêutica que compreende concentrações terapeuticamente efetivas do fator de crescimento epidérmico e do hexapeptídio secretagogo do hormônio de crescimento humano é administrada em um sujeito que sofre dos sintomas de esclerose múltipla e neuromielite óptica e corrige a desmielização causada por células autoreativas no sistema nervoso central.
BRPI0607844A 2005-03-02 2006-02-24 uso do egf e ghrp-6 BRPI0607844B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2005-0043 2005-03-02
CU20050043A CU23529A1 (es) 2005-03-02 2005-03-02 Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune
PCT/CU2006/000001 WO2006092106A2 (es) 2005-03-02 2006-02-24 Combinación de egf/ghrp-6 para la neuroregeneracion del sistema nervioso central posterior al daño autoinmune.

Publications (3)

Publication Number Publication Date
BRPI0607844A2 BRPI0607844A2 (pt) 2010-10-19
BRPI0607844B1 BRPI0607844B1 (pt) 2018-08-28
BRPI0607844B8 true BRPI0607844B8 (pt) 2021-05-25

Family

ID=40280698

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607844A BRPI0607844B8 (pt) 2005-03-02 2006-02-24 uso do egf e ghrp-6

Country Status (18)

Country Link
US (1) US20100093616A1 (pt)
EP (1) EP1870106B1 (pt)
JP (1) JP5001180B2 (pt)
KR (1) KR101255200B1 (pt)
CN (1) CN101180044B (pt)
AT (1) ATE431743T1 (pt)
AU (1) AU2006220154B2 (pt)
BR (1) BRPI0607844B8 (pt)
CA (1) CA2600628C (pt)
CU (1) CU23529A1 (pt)
DE (1) DE602006006903D1 (pt)
ES (1) ES2327562T3 (pt)
MX (1) MX2007010717A (pt)
MY (1) MY142494A (pt)
PT (1) PT1870106E (pt)
RU (1) RU2403913C2 (pt)
WO (1) WO2006092106A2 (pt)
ZA (1) ZA200707020B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
CU24591B1 (es) * 2018-08-21 2022-04-07 Ct Ingenieria Genetica Biotecnologia Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento
ES2967696T3 (es) 2019-04-08 2024-05-03 Giuseppe Scalabrino Factor de crecimiento epidérmico (EGF) y variantes del mismo para tratar o prevenir trastornos desmielinizantes inflamatorios

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9804064D0 (sv) * 1998-11-25 1998-11-25 A & Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
JP3993560B2 (ja) * 2001-08-30 2007-10-17 ステム セル セラピューティクス インコーポレイテッド 神経幹細胞の分化およびその治療用途
CU23043A1 (es) * 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
EP1506997A1 (en) * 2003-08-14 2005-02-16 NeuroProgen GmbH Leipzig Method of generating neural stem cells

Also Published As

Publication number Publication date
ATE431743T1 (de) 2009-06-15
CN101180044A (zh) 2008-05-14
AU2006220154B2 (en) 2010-05-27
ES2327562T3 (es) 2009-10-30
BRPI0607844B1 (pt) 2018-08-28
MY142494A (en) 2010-11-30
AU2006220154A1 (en) 2006-09-08
US20100093616A1 (en) 2010-04-15
CU23529A1 (es) 2010-06-17
WO2006092106A3 (es) 2006-12-14
PT1870106E (pt) 2009-08-25
JP2008531607A (ja) 2008-08-14
CN101180044B (zh) 2010-12-08
WO2006092106A2 (es) 2006-09-08
KR20070107790A (ko) 2007-11-07
EP1870106B1 (en) 2009-05-20
BRPI0607844A2 (pt) 2010-10-19
JP5001180B2 (ja) 2012-08-15
RU2007136280A (ru) 2009-04-10
CA2600628A1 (en) 2006-09-08
DE602006006903D1 (de) 2009-07-02
KR101255200B1 (ko) 2013-04-23
RU2403913C2 (ru) 2010-11-20
ZA200707020B (en) 2009-08-26
CA2600628C (en) 2013-04-09
EP1870106A2 (en) 2007-12-26
MX2007010717A (es) 2007-10-12

Similar Documents

Publication Publication Date Title
ES2496892T3 (es) Formulaciones para el tratamiento de trastornos del tracto respiratorio superior
ECSP077281A (es) Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparación y métodos de uso de los mismos
CU23734A1 (es) Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
UY29700A1 (es) "8-(3-amino-piperidin-1-il)-xantinas, su preparación y su uso como medicamentos
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
UY33616A (es) Compuestos con estructura de imidazotriazinona
BR112012011332A2 (pt) agentes direcionados para gadd45beta
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
DK2190473T3 (da) Peptid med reduceret dimerdannelse
CL2008001560A1 (es) Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico.
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
HN2003000044A (es) Esteres hidroxamato del acido n - (4-fenil sustituido)-antranilico.
AR057239A1 (es) Inmunoglobulinas
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
ZA200707020B (en) Combination of EGF/GHRP-6 for neuroregeneration of central nervous system following autoimmune damage
GT200600106A (es) Agentes endoparasiticidas
MX2024001744A (es) Formulaciones de radiprodil.
BRPI0511125A (pt) usos de ácido 5,6,7-triidroxieptanóico seus e análogos
DE602004009166D1 (de) Neue Analoga von Nitrobenzylthioinosin
DK1891960T3 (da) Farmeceutisk formulering til behandling af hudsygdom
UY30039A1 (es) Uso de derivados heterociclicos benzo-fusionados para el tratamiento de la mania y el trastorno bipolar
ITPG20070053A1 (it) Trattamento ad uso topico per stimolare e mantenere l'erezione del pene.
GT200700037A (es) Derivados de cicloalquilaminoacidos

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA MEMO/INPI/PROC/NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/08/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2711 DE 20-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.